E6201

DRUG3 trials

Sponsors

Eisai Inc., Spirita Oncology, LLC

Conditions

AMLAdvanced Solid TumorsBrain MetastasesCMMLMDSMalignant Melanoma

Phase 1

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors

CompletedNCT00794781

Eisai Inc.Advanced Solid Tumors

Start: 2008-06-22End: 2015-10-15Updated: 2022-10-14

A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations

TerminatedNCT02418000

Spirita Oncology, LLCAML, CMML, MDS

Start: 2015-04-10End: 2017-06-08Updated: 2019-03-20

E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)

TerminatedNCT03332589

Spirita Oncology, LLCBrain Metastases, Malignant Melanoma

Start: 2018-07-02End: 2021-10-11Updated: 2022-05-20

Related Papers

Abstract 5780: E6201, a novel MEK1 inhibitor, suppresses the metastatic capability of triple-negative breast cancer cells

Cancer Research2018-07-014 citations